@Pilbrapros makes a great point. I find it very hard to find an...

@Pilbrapros makes a great point. I find it very hard to find an answer. I think we've all wanted more disclosure from GSS but there must be commercial sensitivities in the agreements which prohibits us from finding out.

@thongo@ElleBelle i've been wondering the same things, will these high testing rates going to convert to rev. I listened to Dr Chant talk about rapid testing in NSW with results available in 20 minutes. We know the 3base platform delivers results in hours so it can't be us. How many of these tests are replacing work done that would've been done by GSS? How much revenue is directly related to the testing numbers? I made this table up from what i could find in the reports (i've double checked the numbers but there may be some errors). SOI, total rev and asia pacific rev from reports. Mkt cap calculated on day the report was released except for 4Q Mkt cap which was as at 30/6.

		Total Rev	Asia Pacific Rev	%RevAsiaPac	Aust Covid Tests	Market Cap
1	FY19	$4.8M	$4.7M	97.9%		$109M
2	H1 FY20	$2.5M	$2.4M	96.0%		$140M
3	H2 FY20	$8.7M	$7.7M	88.5%	2,455,982	$324M
4	H1 FY21	$18.7M	$15.2M	81.3%	8,804,564	$255M
5	3Q FY21	$4.3M	$2.4M	55.8%	4,352,764	$207M
6	4Q FY21 EST	?	?	?	5,071,697	$199.7M

As we know APAC revenue for H1 FY21 was $15.2M and then only $2.4M for 3Q21.

That $2.4 APAC result was with 4.3 million tests and last quarter there was 5.1M - following the number of tests logic maybe that gets us to $3m APAC rev?

In the H1FY21 report:

"As new variants of the virus are detected it is unclear if the vaccines will be effective against them nor how transmissible the variants will be. Our platform technology, 3base™ is less susceptible to these variants and the company has confirmed that our current assay detects all reported variants."

Is this quality of 3base attracting a higher number of kit sales? Does the delta and any other variant change the rev opportunity?

In the recent quarterly there was also comment that USA and Europe kit sales are expected to increase after some earlier delays so this could provide another lift.

As we know, testing rates are through the roof and since July 1 theres been 3,324,905 tests conducted in Australia - we could be looking at 10 million for the quarter.